Cargando…

Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD

Progressive fibrosing interstitial lung disease (PF-ILD) describes a phenotypic subset of interstitial lung diseases characterized by progressive, intractable lung fibrosis. PF-ILD is separate from, but has radiographic, histopathologic, and clinical similarities to idiopathic pulmonary fibrosis. Tw...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shumar, John N., Chandel, Abhimanyu, King, Christopher S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197477/ https://www.ncbi.nlm.nih.gov/pubmed/34070297 http://dx.doi.org/10.3390/jcm10112285

Ejemplares similares

Management of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD)
por: Copeland, Carla R., et al.
Publicado: (2021)

Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
por: Westerink, Lotte, et al.
Publicado: (2022)

Towards the Essence of Progressiveness: Bringing Progressive Fibrosing Interstitial Lung Disease (PF-ILD) to the Next Stage
por: De Sadeleer, Laurens J., et al.
Publicado: (2020)

Nintedanib in Patients With Autoimmune Disease–Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial
por: Matteson, Eric L., et al.
Publicado: (2022)

Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial
por: Cottin, Vincent, et al.
Publicado: (2022)

Impact of progressive fibrosing interstitial lung disease (ILD) in ILD patients complicated with secondary spontaneous pneumothorax
por: Yamakawa, Hideaki, et al.
Publicado: (2021)

CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies
por: Zanatta, Elisabetta, et al.
Publicado: (2023)

Care patterns of patients with chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype
por: Nili, Mona, et al.
Publicado: (2022)

Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial
por: Flaherty, Kevin R., et al.
Publicado: (2022)

Real-world impact of antifibrotics on prognosis in patients with progressive fibrosing interstitial lung disease
por: Niitsu, Takayuki, et al.
Publicado: (2023)

Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease
por: Flaherty, Kevin R, et al.
Publicado: (2017)

Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases
por: Torrisi, Sebastiano Emanuele, et al.
Publicado: (2019)

Progression of fibrosing interstitial lung disease
por: Wong, Alyson W., et al.
Publicado: (2020)

Nationwide epidemiologic study for fibrosing interstitial lung disease (F-ILD) in South Korea: a population-based study
por: Joung, Kyung-In, et al.
Publicado: (2023)

Investigating significant health trends in progressive fibrosing interstitial lung disease (INSIGHTS-ILD): rationale, aims and design of a nationwide prospective registry
por: Behr, Juergen, et al.
Publicado: (2023)

The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD
por: Kolb, Martin, et al.
Publicado: (2022)

Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
por: Cottin, Vincent, et al.
Publicado: (2021)

The Burden of Progressive-Fibrosing Interstitial Lung Diseases
por: Cottin, Vincent, et al.
Publicado: (2022)

Moving from PF-ILD to PPF
por: Bhattacharyya, Parthasarathi
Publicado: (2023)

Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications
por: Erre, Gian Luca, et al.
Publicado: (2021)

The natural history of progressive fibrosing interstitial lung diseases
por: Kolb, Martin, et al.
Publicado: (2019)

The natural history of progressive fibrosing interstitial lung diseases
por: Brown, Kevin K., et al.
Publicado: (2020)

Predictors of Mortality in Progressive Fibrosing Interstitial Lung Diseases
por: Chen, Xianqiu, et al.
Publicado: (2021)

The Role of Radiology in Progressive Fibrosing Interstitial Lung Disease
por: Abu Qubo, Ahmad, et al.
Publicado: (2022)

Acute exacerbations of progressive-fibrosing interstitial lung diseases
por: Kolb, Martin, et al.
Publicado: (2018)

Role of imaging in progressive-fibrosing interstitial lung diseases
por: Walsh, Simon L.F., et al.
Publicado: (2018)

Burden of illness in progressive fibrosing interstitial lung disease
por: Singer, David, et al.
Publicado: (2022)

ChILD – Children's interstitial lung disease
Publicado: (2018)

Pulmonary Hypertension in Interstitial Lung Disease: Updates in Disease, Diagnosis, and Therapeutics
por: Haynes, Zachary A., et al.
Publicado: (2023)

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
por: Wollin, Lutz, et al.
Publicado: (2019)

Progressive fibrosing interstitial lung disease: prevalence and clinical outcome
por: Kwon, Byoung Soo, et al.
Publicado: (2021)

Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective
por: Albera, Carlo, et al.
Publicado: (2021)

Real-life prevalence of progressive fibrosing interstitial lung diseases
por: Gagliardi, Maureen, et al.
Publicado: (2021)

Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases
por: Brown, Kevin K., et al.
Publicado: (2022)

Diagnostic and prognostic biomarkers for progressive fibrosing interstitial lung disease
por: Watase, Mayuko, et al.
Publicado: (2023)

Management of Fibrosing Interstitial Lung Diseases
por: Maher, Toby M., et al.
Publicado: (2019)

Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases
por: Cottin, Vincent
Publicado: (2019)

Pulmonary Hypertension in Interstitial Lung Disease: Management Options to Move Beyond Supportive Care
por: Fabyan, Kimberly D., et al.
Publicado: (2023)

Impact of ILD-Specific Therapies on Perioperative Course in Patients with Progressive Interstitial Lung Disease Undergoing Lung Transplantation
por: Munker, Dieter, et al.
Publicado: (2023)

Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)
por: Nasser, Mouhamad, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tom7a2o8uc04eldnet7u8s6mun